SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Copeland GP, Jones D, Walters M. POSSUM: a scoring system for surgical audit. Br J Surg. 1991; 78: 355-360.
  • 2
    Extermann M, Bonetti M, Sledge GW, O'Dwyer PJ, Bonomi P, Benson AB3rd., MAX2—a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer. 2004; 40: 1193-1198.
  • 3
    Extermann M, Chen H, Cantor AB, et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer. 2002; 38: 1466-1473.
  • 4
    Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest. 2000; 18: 521-529.
  • 5
    Hurria A, Brogan K, Panageas KS, et al. Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Drugs Aging. 2005; 22: 709-715.
  • 6
    Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008; 6: 109-118.
  • 7
    Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003; 44: 2069-2076.
  • 8
    Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2000; 37: 351-360.
  • 9
    Freyer G, Geay JF, Touzet S, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005; 16: 1795-1800.
  • 10
    Bachelot T, Ray-Coquard I, Catimel G, et al. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol. 2000; 11: 151-156.
  • 11
    Hurria A, Hurria A, Brogan K, et al. Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging. 2005; 22: 785-791.
  • 12
    Ray-Coquard I, Le Cesne A, Rubio MT, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol. 1999; 17: 2840-2846.
  • 13
    Martell RE, Peterson BL, Cohen HJ, et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB coordinated intergroup study. Cancer Chemother Pharmacol. 2002; 50: 37-45.
  • 14
    Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992; 41: 237-248.
  • 15
    Gronberg BH, Sundstrom S, Kaasa S, et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer. 2010; 46: 2225-2234.
  • 16
    Zauderer M, Patil S, Hurria A. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treatment. 2009; 117: 205-210.
  • 17
    Ray-Coquard I, Ghesquiere H, Bachelot T, et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer. 2001; 85: 816-822.
  • 18
    Ray-Coquard I, Borg C, Bachelot T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003; 88: 181-186.
  • 19
    Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007; 43: 14-34.
  • 20
    Zubrod CS, Frei EIII, Brindley C, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis. 1960; 11: 7-33.
  • 21
    Lawton MP. Scales to measure competence in everyday activities. Psychopharmacol Bull. 1988; 24: 609-614.
  • 22
    Guigoz Y, Vellas B, Garry PJ. Mini Nutritional Assessment: a practical assessment tool for grading nutritional state of elderly patients. In: Vellas BJ, Guigoz Y, Garry PJ, Albarede JL, eds. Facts Research and Intervention in Geriatrics. 3rd ed. New York: Serdi Publishing Company; 1997: 15-60.
  • 23
    Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198.
  • 24
    Sheikh J, Yesavage JA. Geriatric Depression Scale (GDS). Recent evidence and development of a shorter version. Clin Gerontol. 1986; 5( 1/2): 165-171.
  • 25
    Hosmer D, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: John Wiley & Sons, Inc.; 2000.
  • 26
    Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD. Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets. Med Decis Making. 2001; 21: 45-56.
  • 27
    Extermann M, Boler I, Brown RH, et al. Comparison of older patients receiving chemotherapy in the community versus an academic cancer center [abstract]. Crit Rev Oncol Hematol. 2009; 72( suppl 1): S56.
  • 28
    Popa M, Wallace K, Brunello A, Extermann M. The impact of polypharmacy on toxicity from chemotherapy in elderly patients: focus on cytochrome P-450 inhibition and protein binding effects [abstract]. J Clin Oncol. 2008; 26( 15S). Abstract 9505.
  • 29
    Chen H, Cantor A, Meyer J, et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer. 2003; 97: 1107-1114.
  • 30
    O'Leary CA, Extermann M. Chemotherapy dose adjustment after severe toxicity in older cancer patients [abstract]. J Clin Oncol. 2008; 26(May 20 suppl). Abstract 9627.
  • 31
    Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005; 104: 788-793.
  • 32
    Hurria A, Rosen C, Hudis C, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006; 54: 925-931.
  • 33
    Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001; 38: 399-403.
  • 34
    Vellas B, Guigoz Y, Baumgartner M, Garry PJ, Lauque S, Albarede JL. Relationships between nutritional markers and the Mini-Nutritional Assessment in 155 older persons. J Am Geriatr Soc. 2000; 48: 1300-1309.
  • 35
    Sweeney CJ, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer. 2001; 92: 2639-2647.
  • 36
    Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011; 29: 3457-3465.